Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.

At 52 weeks, relapses were observed in 10.1% of patients treated with avacopan compared with 21.0% in the GC group; although this difference did not reach statistical significance, it suggests a promising trend toward relapse reduction while minimizing GC-related toxicity [ 26 ].

also in 111,027 other papers